Abstract:Clostridioides difficile (C. difficile) is a Gram-positive, spore-forming anaerobic bacterium emerged as a leading cause of diarrhea globally. CDI's (Clostridioides difficile infection) impact on healthcare systems is concerning due to high treatment cost and increased hospitalisation time. The incidence of CDI has been influenced by hypervirulent strains such as the 027 ribotype, responsible for significant outbreaks in North America and Europe. CDI's epidemiology has evolved, showing increased community-acquired cases alongside traditional hospital-acquired infections. Mortality rates remain high, with recurrent infections further elevating the risk. Transmission of C. difficile primarily occurs via spores, which survive in healthcare settings and play a pivotal role in transmission. Not only health workers, but also the food chain could have a significant impact on the transmission of infection, although no confirmed foodborne cases have been documented. Pathogenicity of C. difficile involves spore germination and toxin production. Toxins A and B can cause cellular damage and inflammatory responses in the host, leading to colitis. Clinical picture can range from mild diarrhea to fulminant colitis with toxic megacolon, and bowel perforation. Risk factors for CDI include antibiotic exposure, advanced age, hospitalization, and use of proton pump inhibitors. Patients who experience abdominal surgery or patients with inflammatory bowel disease (IBD) are particularly susceptible due to their compromised gut microbiota. Management of CDI has evolved, with fidaxomicin emerging as a superior treatment option over vancomycin for initial and recurrent infections due to its reduction of recurrence rate. Faecal microbiota transplantation (FMT) is effective for recurrent CDI, restoring gut eubiosis. Bezlotoxumab, a monoclonal antibody against C. difficile toxin B, has shown promise in reducing recurrence rates. Severe cases of CDI may require surgical intervention, particularly in instances of toxic megacolon or bowel perforation. In conclusion, CDI remains a significant clinical entity. Further research are needed to improve patients' outcome and reduce the burden on healthcare systems.

Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines

The management of Clostridioides difficile infection: from empirism to evidence

Clostridioides Difficile: A Concise Review of Best Practices and Updates

Controversies in the Prevention and Treatment of Clostridioides difficile Infection in Adults: A Narrative Review

The epidemiology and management of Clostridioides difficile infection—A clinical update

Therapeutics involved in managing initial and recurrent Clostridium difficile infection: An updated literature review

[Clostridioides difficile infections: Update and therapeutic guidelines]

Advances in Therapeutic Strategies for the Management of Clostridioides difficile Infection

Fighting Against Clostridioides Difficile Infection: Current Medications

Treatment outcomes of mild to moderate Clostridioides difficile infection in inflammatory bowel disease: an Australian experience

Guideline for the management of Clostridioides difficile infection in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2024 update

The always evolving diagnosis and management of Clostridioides difficile colitis: What you need to know

Clostridioides difficile infection: an update

Systematic review of guidelines for the diagnosis and treatment of Clostridioides difficile infection

[Need for improvement in the care of patients with Clostridioides difficile infections (CDI) - expert opinion in international comparison]

Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies

Current international and national clinical guidelines for the prevention, diagnosis, and treatment of Clostridioides difficile infection in adults and children: an overview, criticisms, and applicability in real-life clinical practice

The Evaluation of Fecal Microbiota Transplantation Vs Vancomycin in a Clostridioides Difficile Infection Model.

Diagnostic and therapeutic management of Clostridioides difficile infection

Clostridioides difficile Infection: A Clinical Review of Pathogenesis, Clinical Considerations, and Treatment Strategies

Fidaxomicin versus oral vancomycin for Clostridioides difficile infection among patients at high risk for recurrence based on real-world experience